MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Rating of “Moderate Buy” from Analysts

MBX Biosciences, Inc. (NASDAQ:MBX) has been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $77.00.

A number of research analysts have weighed in on MBX shares. Wall Street Zen lowered MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. UBS Group restated a “buy” rating and set a $90.00 price target on shares of MBX Biosciences in a research report on Thursday, July 23rd. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a research note on Friday, August 21st. They issued an “overweight” rating and a $88.00 target price on the stock. Truist Financial lifted their price objective on MBX Biosciences from $70.00 to $88.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Citigroup reiterated an “outperform” rating on shares of MBX Biosciences in a report on Tuesday, May 12th.

MBX Biosciences Stock Down 5.1%

Shares of NASDAQ MBX opened at $63.00 on Friday. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of -26.14 and a beta of 0.10. The company’s 50-day simple moving average is $61.80 and its 200-day simple moving average is $42.99. MBX Biosciences has a 52-week low of $9.63 and a 52-week high of $72.64.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). Equities research analysts anticipate that MBX Biosciences will post -3.11 EPS for the current fiscal year.

Institutional Investors Weigh In On MBX Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC raised its holdings in shares of MBX Biosciences by 28.9% in the 4th quarter. CWM LLC now owns 1,784 shares of the company’s stock valued at $56,000 after buying an additional 400 shares during the period. Royal Bank of Canada lifted its holdings in MBX Biosciences by 59.6% during the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $49,000 after buying an additional 572 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of MBX Biosciences by 64.7% in the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after acquiring an additional 689 shares in the last quarter. Strs Ohio boosted its holdings in MBX Biosciences by 128.6% in the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after purchasing an additional 900 shares during the period. Finally, State of Wyoming purchased a new stake in MBX Biosciences during the 2nd quarter worth about $58,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.